- Home
- IQV vs IR Comparison
IQV vs IR Comparison
Compare IQV & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQV | IR |
|---|---|---|
| Founded | 1982 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 33.9B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | IQV | IR |
|---|---|---|
| Price | $235.75 | $88.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $242.60 | $92.00 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.09% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.30 | 1.35 |
| Revenue | ★ $15,904,000,000.00 | $7,458,300,000.00 |
| Revenue This Year | $6.14 | $8.09 |
| Revenue Next Year | $5.44 | $4.55 |
| P/E Ratio | ★ $32.26 | $65.72 |
| Revenue Growth | 3.85 | ★ 4.20 |
| 52 Week Low | $134.65 | $65.61 |
| 52 Week High | $247.05 | $95.85 |
Technical Indicators
Market Signals| Indicator | IQV | IR |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 60.22 |
| Support Level | $227.99 | $84.93 |
| Resistance Level | $244.16 | $90.85 |
| Average True Range (ATR) | 5.81 | 2.07 |
| MACD | -0.83 | -0.09 |
| Stochastic Oscillator | 39.14 | 62.67 |
Price Performance
Historical ComparisonAbout IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.2 billion in revenue in 2024.